Winnie Kwai Yu Chan1, Wun Fung Hui2. 1. Department of Paediatrics, Queen Elizabeth Hospital, Hong Kong, SAR, China. chankyw@ha.org.hk. 2. Department of Paediatrics, Queen Elizabeth Hospital, Hong Kong, SAR, China.
Abstract
BACKGROUND: High-dose methotrexate therapy (HDMTX) is a common form of chemotherapy used in children with high-grade malignancy such as osteosarcoma. Treatment with HDMTX requires careful monitoring of drug levels with folinic acid (leucovorin) rescue therapy. Toxicity from methotrexate is not uncommon and sometimes causes significant morbidity and mortality. CASE-DIAGNOSIS/TREATMENT: We report an 11-year-old child whose 24-h post-HDMTX serum level was 651.8 μmol/L (recommended level <20 μmol/L), which was complicated by septic shock and progressive renal and liver failure. As carboxypeptidase (glucarpidase) was not available locally, she was treated with the sequential use of charcoal hemoperfusion (CHP) and single-pass albumin dialysis (SPAD). The patient recovered without complications. Both liver and renal function recovered with no significant late sequelae. CONCLUSION: CHP and SPAD are effective extracorporeal methods of removing methotrexate. They provide alternative treatment options for critical care nephrologists in the management of methotrexate toxicity.
BACKGROUND: High-dose methotrexate therapy (HDMTX) is a common form of chemotherapy used in children with high-grade malignancy such as osteosarcoma. Treatment with HDMTX requires careful monitoring of drug levels with folinic acid (leucovorin) rescue therapy. Toxicity from methotrexate is not uncommon and sometimes causes significant morbidity and mortality. CASE-DIAGNOSIS/TREATMENT: We report an 11-year-old child whose 24-h post-HDMTX serum level was 651.8 μmol/L (recommended level <20 μmol/L), which was complicated by septic shock and progressive renal and liver failure. As carboxypeptidase (glucarpidase) was not available locally, she was treated with the sequential use of charcoal hemoperfusion (CHP) and single-pass albumin dialysis (SPAD). The patient recovered without complications. Both liver and renal function recovered with no significant late sequelae. CONCLUSION: CHP and SPAD are effective extracorporeal methods of removing methotrexate. They provide alternative treatment options for critical care nephrologists in the management of methotrexatetoxicity.
Entities:
Keywords:
Hemoperfusion; Methotrexate; Pediatrics; Single-pass albumin dialysis; Toxicity
Authors: Jeffrey M Saland; Patrick J Leavey; Robert O Bash; Eleonora Hansch; Gerald S Arbus; Raymond Quigley Journal: Pediatr Nephrol Date: 2002-08-09 Impact factor: 3.714
Authors: P Picci; M Mercuri; S Ferrari; M Alberghini; A Briccoli; C Ferrari; E Pignotti; G Bacci Journal: Ann Oncol Date: 2009-11-04 Impact factor: 32.976
Authors: Igor M Sauer; Max Goetz; Ingo Steffen; Gesa Walter; Daniel C Kehr; Ruth Schwartlander; Yoon J Hwang; Andreas Pascher; Joerg C Gerlach; Peter Neuhaus Journal: Hepatology Date: 2004-05 Impact factor: 17.425
Authors: Mariann D Churchwell; Deborah A Pasko; William E Smoyer; Bruce A Mueller Journal: Nephrol Dial Transplant Date: 2008-08-22 Impact factor: 5.992
Authors: Rupesh Raina; Manpreet K Grewal; Martha Blackford; Jordan M Symons; Michael J G Somers; Christoph Licht; Rajit K Basu; Sidharth Kumar Sethi; Deepa Chand; Gaurav Kapur; Mignon McCulloch; Arvind Bagga; Vinod Krishnappa; Hui-Kim Yap; Marcelo de Sousa Tavares; Timothy E Bunchman; Michelle Bestic; Bradley A Warady; Maria Díaz-González de Ferris Journal: Pediatr Nephrol Date: 2019-08-24 Impact factor: 3.714
Authors: Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood Journal: Clin J Am Soc Nephrol Date: 2022-03-02 Impact factor: 10.614
Authors: Jenna Essink; Sydney Berg; Jaka Montange; Andrew Sankey; Veronica Taylor; Jeffrey Salomon Journal: J Investig Med High Impact Case Rep Date: 2022 Jan-Dec